FORM	4
------	---

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)												
1. Name and Address of Reporting Person <sup>*</sup> – BLANK FABIAN			2. Issuer Name and ENZO BIOCHEM			Symbol		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) C/O ENZO BIOCHEM, AVENUE	<sup>rst)</sup> NC., 527 MA	DICONT	Date of Earliest Tr 04/23/2020	ansaction (M	lonth/	Day/Year	)		Officer (give title below)Oth	er (specify below	w)	
, , , , , , , , , , , , , , , , , , ,	reet)	4	. If Amendment, Da	te Original F	iled(N	fonth/Day/Y	ear)		6. Individual or Joint/Group Filing(Check A _X_Form filed by One Reporting Person Form filed by More than One Reporting Person	Applicable Line	)	
NEW YORK, NY 10022												
(City) (S	tate)	(Zip)		Table I - N	on-De	erivative	Securitie	s Acqu	nired, Disposed of, or Beneficially Owne	d		
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	~	3. Transacti Code (Instr. 8)	-	4. Securi (A) or Di (Instr. 3,	isposed of		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form:	7. Nature of Indirect Beneficial	
			(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in SEC 1474 (9-02) this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(e.g., puts, calls, warrants, options, convertible securities)														
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	· · · · · · · · · · · · · · · · · · ·	4. 5. Number Transaction of Derivative Code Securities Acquired (A) or Disposed of (D) (Instr. 3, 4,		6. Date Exercisab Expiration Date (Month/Day/Year	7. Title and Amount of Underlying Securities		Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported	Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficial			
				Code	v	and 5) (A)	(D)	Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)	(I) (Instr. 4)	
Stock Option (to acquire Common Stock)	\$ 2.65	04/23/2020		А		83,333		04/23/2021 <sup>(1)</sup>	04/23/2025	Common Stock	83,333	\$ 0	83,333	D	

### **Reporting Owners**

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
BLANK FABIAN C/O ENZO BIOCHEM, INC. 527 MADISON AVENUE NEW YORK, NY 10022	Х						

## Signatures

 /s/ Fabian Blank
 04/29/2020

 \*\*Signature of Reporting Person
 Date

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The Reporting Person was granted 83,333 stock options. The stock options have a five-year term and will vest in two equal installments, one on the first anniversary of the grant date and the second on the second anniversary of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.